6814.TWO Lukas Biomedical Inc.
- Market cap
- TWD 750M
- P/E
- -
- P/B
- 3.94x
- ROE
- -35.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6814.TWO undervalued?
Graham numberThe Graham number of Lukas Biomedical Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lukas Biomedical Inc. fundamental analysis
No fundamental analysis for Lukas Biomedical Inc. yet.
Lukas Biomedical Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lukas Biomedical Inc.
Lukas Biomedical Inc. engages in the wholesale and retail of cosmetics in Taiwan. The company operates through E-Commerce Department, Medical Management Business, Cell Products Department, and Pharmaceutical Market Development Department segments. It also researches and develops immune cell medical technology for regenerative medicine and adjuvant treatment; engages in clinical trials; distributes immune cell therapy culture technology; and leases building equipment. In addi…
Full company profileLukas Biomedical Inc. financial statements
Lukas Biomedical Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 153M | 181M | 158M | 185M | 232M | 190M | 179M |
| Gross Profit | 100M | 118M | 96.1M | 97.9M | 134M | 113M | 108M |
| Operating Income | -7.03M | -6.48M | -43.1M | -48.5M | -43.6M | -92.1M | -81.1M |
| EBITDA | 47.7M | 43.3M | -361K | -10.9M | -12.6M | -62.9M | -55.5M |
| Net Income | -6.99M | -10.5M | -49.5M | -50.1M | -47.4M | -94.4M | -85.6M |
| EPS | -0.20 | -0.32 | -1.50 | -1.35 | -1.28 | -2.38 | -2.05 |
| Balance Sheet | |||||||
| Total Assets | 556M | 524M | 531M | 480M | 441M | 477M | 427M |
| Total Liabilities | 255M | 233M | 245M | 152M | 161M | 151M | 187M |
| Shareholders' Equity | 301M | 291M | 287M | 327M | 280M | 326M | 240M |
| Cash & Short-term Investments | 40.5M | 39.0M | 64.8M | 40.3M | 31.8M | 64.7M | 34.7M |
| Total Debt | 230M | 212M | 221M | 112M | 126M | 115M | - |
| Cash Flow | |||||||
| Operating Cash Flow | 59.1M | 29.0M | -16.2M | -7.44M | -11.7M | -70.5M | -61.4M |
| Capital Expenditure | 63.9M | 8.99M | 10.0M | 2.98M | 2.66M | 6.81M | 8.52M |
| Free Cash Flow | -4.81M | 20.0M | -26.2M | -10.4M | -14.4M | -77.3M | -69.9M |
| Ratios | |||||||
| ROE | -2.3% | -3.6% | -17.3% | -15.3% | -16.9% | -29.0% | -35.7% |
| ROA | -1.3% | -2.0% | -9.3% | -10.4% | -10.7% | -19.8% | -20.1% |
| Net Profit Margin | -4.6% | -5.8% | -31.4% | -27.1% | -20.4% | -49.7% | -47.7% |
| Debt to Equity | 0.76x | 0.73x | 0.77x | 0.34x | 0.45x | 0.35x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lukas Biomedical Inc. dividends
Lukas Biomedical Inc. has not paid dividends in the last 7 fiscal years.
Who owns Lukas Biomedical Inc.
Ownership data of Lukas Biomedical Inc. is not available yet.
Lukas Biomedical Inc. company profile
- Company name
- Lukas Biomedical Inc.
- Ticker
- 6814.TWO
- ISIN
- TW0006814007
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 87
- Fiscal year end
- December
- Address
- No. 14-16, Zhongxiao Road, New Taipei City, Taiwan, 220065
- Phone
- 886 2 2950 0027
- Website
- lukas-biomedical.com
About Lukas Biomedical Inc.
Lukas Biomedical Inc. engages in the wholesale and retail of cosmetics in Taiwan. The company operates through E-Commerce Department, Medical Management Business, Cell Products Department, and Pharmaceutical Market Development Department segments. It also researches and develops immune cell medical technology for regenerative medicine and adjuvant treatment; engages in clinical trials; distributes immune cell therapy culture technology; and leases building equipment. In addition, the company involved in the new immune cell research and development, new product development, clinical trials, and production of cell reagents; and provision of brand management and medical management services. Lukas Biomedical Inc. was founded in 2002 and is based in New Taipei City, Taiwan.
Lukas Biomedical Inc. management
3- Chaoan LiuManager
- Wen Xuan ChengAccounting Supervisor
- Mr. Ping-Chung LiuChief Medical Officer & Head of the Cell Products Department